HCW Biologics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCWB research report →
Price Chart
About the company
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
- CEO
- Hing C. Wong
- IPO
- 2021
- Employees
- 35
- HQ
- Miramar, FL, US
Get TickerSpark's AI analysis on HCWB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $260.42K
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.04
- P/B
- 0.23
- EV/EBITDA
- -2.05
- Div Yield
- 0.00%
- Gross Margin
- 95.72%
- Op Margin
- -80.87%
- Net Margin
- -53.10%
- ROE
- -63.04%
- ROIC
- -34.88%
Latest fiscal year · YoY change
- Revenue
- $54.23K-97.9%
- Gross Profit
- $10.85K-98.9%
- Op Income
- $-11,257,288
- Net Income
- $-7,959,709+73.5%
- EPS
- $-63.78+65.7%
- OCF Growth
- +5.9%
- FCF Growth
- +7.6%
- 52W High
- $23.94
- 52W Low
- $0.70
- 50D MA
- $1.35
- 200D MA
- $3.64
- Beta
- 2.27
- RSI (14)
- 24
- Avg Volume
- 379.38K
No earnings-call transcripts are available for HCWB yet.
- Free Float
- 85.8%
- Shares Outstanding
- 347.64K
- Float Shares
- 298.16K
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 46.02K | ▼ 6.11K |
| State Street Corp | 29.02K | ▲ 29.02K |
| Citadel Advisors LLC | 19.94K | ▼ 6.14K |
| Vanguard Group Inc | 15.43K | 0 |
| Geode Capital Management, LLC | 11.74K | ▲ 11.74K |
| Vanguard Fiduciary Trust Co | 6.51K | ▲ 1 |
| Tower Research Capital LLC (Trc) | 4.12K | ▼ 10.72K |
| Connective Capital Management, LLC | 3.34K | ▲ 3.34K |
| Vanguard Capital Management LLC | 2.00K | ▲ 2 |
| Golden State Wealth Management, LLC | 1.67K | 0 |
| Citigroup Inc | 514 | ▲ 514 |
| Ubs Group AG | 6 | ▲ 5 |
Held by 6 ETFs
Biggest fund positions in HCWB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Wong Hing C | buy | 23,210 |
| Jul 29, 26 | Flowers Lee | buy | 7,736 |
| Jul 29, 26 | GARRETT SCOTT T | buy | 7,736 |
| May 22, 26 | Wong Hing C | buy | 113,879 |
| May 22, 26 | Wong Hing C | buy | 113,879 |
| May 22, 26 | GARRETT SCOTT T | buy | 177,936 |
| May 22, 26 | GARRETT SCOTT T | buy | 177,936 |
| May 22, 26 | Byam Rebecca | buy | 14,235 |
| May 22, 26 | Byam Rebecca | buy | 14,235 |
| May 16, 25 | Wong Hing C | buy | 8,054 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HCWB coverage
Recent articles, reports, and earnings notes.
No research on HCWB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HCWB report →HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
globenewswire.com · Nov 16
HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
globenewswire.com · Nov 6
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting
globenewswire.com · Nov 6
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
globenewswire.com · Nov 5
HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September
defenseworld.net · Oct 12
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
globenewswire.com · Oct 9
HCW Biologics Announces Pricing of $1.5 Million Private Placement
globenewswire.com · Sep 24
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.